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S U M M A R Y
Background: Tuberculosis (TB) in penitentiary services (prisons) is a major challenge to TB control. This
review article describes the challenges that prison systems encounter in TB control and provides
solutions for the more efﬁcient use of limited resources based on the three pillars of the post-2015 End
TB Strategy. This paper also proposes research priorities for TB control in prisons based on current
challenges.
Methods: Articles (published up to 2011) included in a recent systematic review on TB control in prisons
were further reviewed. In addition, relevant articles in English (published 1990 to May 2014) were
identiﬁed by searching keywords in PubMed and Google Scholar. Article bibliographies and conference
abstracts were also hand-searched.
Results: Despite being a serious cause of morbidity and mortality among incarcerated populations, many
prison systems encounter a variety of challenges that hinder TB control. These include, but are not
limited to, insufﬁcient laboratory capacity and diagnostic tools, interrupted supply of medicines, weak
integration between civilian and prison TB services, inadequate infection control measures, and low
policy priority for prison healthcare.
Conclusions: Governmental commitment, partnerships, and sustained ﬁnancing are needed in order to
facilitate improvements in TB control in prisons, which will translate to the wider community.
 2015 World Health Organization. Published by Elsevier Ltd on behalf of International Society for
Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Tuberculosis (TB) remains a major public health problem,
posing speciﬁc challenges in numerous geographical areas,
particularly in low- and middle-income countries (LMICs) where
more than 80% of the global TB burden resides.1 Additionally, with
the current slow (2%) annual decline in TB incidence and the
emergence of drug-resistant TB and TB/HIV co-infection, most* Corresponding author. Tel.: +45 45 33 66 49.
E-mail address: daram@who.int (M. Dara).
http://dx.doi.org/10.1016/j.ijid.2014.12.029
1201-9712/ 2015 World Health Organization. Published by Elsevier Ltd on behalf of Int
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).LMICs will not meet the Millennium Development Goals (MDGs)
for TB control by 2015 set by the United Nations.1 Despite recently
gained increased public and political awareness, TB remains a
major infectious disease in prison systems, such as in Eastern
Europe, for several reasons. These include, but are not limited to,
the high prevalence of drug-resistant TB forms, i.e. multi- and
extensively drug-resistant TB (M/XDR-TB),1–14 and intravenous
drug use among HIV-infected individuals, which makes prison
populations more susceptible to the development of TB.15
Prisons are considered reservoirs facilitating Mycobacterium
tuberculosis (MTB) transmission within their walls, as well as to the
community at large. Transmission occurs through prison staff,ernational Society for Infectious Diseases. This is an open access article under the CC
Table 1
Key barriers to tackling TB in prisons according to the three pillars of the End TB
Strategy
Pillar 1: Integrated, patient-centred care and prevention
Lack of laboratory capacity, insufﬁcient quality control, and absence of
new and improved diagnostic methods
Interrupted supply of quality medicines
Absence of an efﬁcient mechanism for direct observation of treatment
Lack of adequate medical facilities
Lack of collaborative TB/HIV activities
Emerging drug resistance
Intravenous drug use among prison populations
Lack of drug substitution and needle exchange programmes
Lack of safer sex programmes for HIV prevention
Limited social support of vulnerable populations
Limited attention to comorbidities (HIV, hepatitis, psychiatric disease)
Weak integration between civilian and prison TB services, continuum
of care for released prisoners
High incarceration rate
Pillar 2: Bold policies and supportive systems
Low priority that policymakers give to health care (including TB) within
the prison system
Insufﬁcient commitment of prison authorities to address TB prevention,
control, and care
Unclear responsibilities of different ministries and health authorities
Stewardship of prison health, mismanagement of TB control in penitentiary
institutions
Shortage of qualiﬁed and motivated human resources
Shortage of staff training/education and appreciation
Limited or poor patient education
Stigmatization of prisoners with TB
Lack of access to prisons by community representatives, NGOs,
and organizations with the capacity to support the vulnerable population
Insufﬁcient surveillance, supervision, monitoring, and evaluation systems
Inadequate IC measures due to overcrowding and/or organizational and legal
challenges in the timely separation of patients
Pillar 3: Intensiﬁed research and innovation
Lack of funding
Lack of commitment by research institutes
Legal difﬁculties with research in prison systems
TB, tuberculosis; NGO, non-governmental organization; IC, infection control.
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latent TB infection (LTBI) and active TB disease in prison systems
are reported to be much higher than the average estimates in the
general population, irrespective of the economic status and the
population TB burden of the country.16 In European prisons,
the prevalence of TB is estimated to be up to 17 times higher than
in the general population.17 A similar epidemiological situation
has been described in LMICs, including Bangladesh, Thailand,
Ethiopia, and Brazil, where TB prevalence has been reported to
be almost four-, eight-, seven-, and 64-times higher, respectively,
among prisoners compared to the general population.18–27
Factors known to contribute to the transmission of MTB strains
and that hamper TB control are overcrowding, delayed case
detection, poor contact detection, inadequate treatment of
infectious cases, high turnover of prisoners, and poor implemen-
tation of TB infection control (IC) measures.28,29 In addition,
limited access to timely and quality health care services further
exacerbate the situation.
In response to the continuing challenges facing the control of
TB and M/XDR-TB, and as the current Global Plan to Stop TB (Stop
TB Strategy) 2011–2015 is in its ﬁnal year, the World Health
Organization (WHO) has recently developed the post-2015 End
TB Strategy with the goal to end the TB epidemic by 2035.30 In
order to deﬁne strategies that efﬁciently address the End TB
Strategy targets, knowledge about solutions for improved TB
control in prison systems is needed. In this review, we summarize
published knowledge on the challenges of TB control in prison
systems and discuss potential solutions, including research
priorities for TB control in prisons, in relation to the three pillars
of the End TB Strategy.
2. Methods
Articles included in a recently published systematic review on
TB control in prison services by Vinkeles Melchers et al.31 were
reviewed; these publications were dated up to June 2011. In
addition, relevant articles in English were identiﬁed by searching
PubMed and Google Scholar, with a temporal range of 1990 to May
2014. Studies were identiﬁed using combinations of the search
terms ‘‘Tuberculosis or TB’’, ‘‘TB Control’’, ‘‘Management’’, ‘‘Public
Health’’, ‘‘Prison* or Jail*’’, and ‘‘Prisoner* or Inmate*’’. Studies in
languages other than English and studies published before
1990 were excluded. Articles were also excluded if they described
challenges in TB control among populations other than prisoners
(e.g., TB contact tracing in the community, health care workers).
The selection of articles was based on their public health relevance
to TB control in prisons. The references of selected articles were
also evaluated to identify additional relevant publications. In
addition, conference abstracts of the International Union Against
Tuberculosis and Lung Diseases and publications from the WHO
over the last 23 years were screened for relevant articles. A total of
637 citations and 332 abstracts were screened, resulting in the
inclusion of 96 publications in this review. Because no systematic
variables were extracted from the publications included, the
challenges and solutions have not been rated on the quality and
validity of the evidence.
3. Results and discussion: current evidence
Barriers to tackling TB in prisons are complex and linked
strongly to other aspects of both the health and criminal justice
systems, and with the cultural, historical, and economic situations
of each country. These barriers are summarized in Table 1,32 and
are discussed below in relation to the three pillars of the End TB
Strategy.3.1. Pillar 1: Integrated, patient-centred care and prevention
3.1.1. Universal drug-susceptibility testing and systematic screening
of contacts and high-risk groups
The lack of well-equipped laboratory facilities in prisons is well
documented.1,4,20,22,33,34 In addition, a systematic review found
that approximately 21% of all studies reporting on TB screening in
prisons described the lack of a well-organized health system,31
potentially leading to the ongoing spread of TB to other prisoners,
prison staff, visitors, and to the general population upon release
from the prison.23,35,36 In the absence of adequate diagnostic tools
in the prison services, health professionals attempt to use the
diagnostic capacity of the civilian sector through national TB
programmes (NTPs), such as sputum smear microscopy, chest
radiography, and sputum culture.34 The use of diagnostic services
external to the prison system may, however, lead to a delay in
diagnosis due to a lack of coordination between the prison and
the civilian sector laboratory networks.17,37,38
Another main challenge to TB diagnosis is the quality of the
bacteriological services. Sputum smear microscopy is not always
performed with quality control. Microscopes are poorly main-
tained, staff may lack quality training in the use of diagnostic
tools,22 and quality assurance including proﬁciency testing is
rarely done.22,39 The introduction of the GeneXpert MTB/RIF assay
is considered an important breakthrough in the ﬁght against TB
and multidrug-resistant (MDR)-TB. For the ﬁrst time, a molecular
test is simple and robust enough to be introduced outside the
conventional or reference laboratory setting, detecting TB and
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provides results directly from the sputum sample within 2 h and
performs well, particularly in sputum smear-positive patients,
with an overall sensitivity of 90.4% and speciﬁcity of 98.4%.42
The GeneXpert MTB/RIF assay is suitable for use at the district and
sub-district levels, including within the prison system, and should
not be restricted to the central/reference laboratory level only.
The current availability of GeneXpert machines in prisons is
unclear and this likely differs from country to country. Although
testing with GeneXpert MTB/RIF does not require additional
laboratory equipment, the sophisticated nature of the device
requires care in handling, i.e., a stable and uninterrupted electrical
or battery supply to avoid interruption of the procedure and
subsequent loss of results, security against theft, adequate storage
space for the cartridges, and dedicated staff to perform testing.40
Addressing this challenge requires general health system strength-
ening,5,6,43,44 including the prison sector and especially in LMICs.
High-quality laboratory services with up-to-date biosafety mea-
sures,19 updated and renewed detention centres45 and TB prison
hospitals, and continuous training programmes for both staff and
prisoners should also be emphasized.24,34,46
3.1.2. Ensure equitable access to quality treatment for all people with
TB, including drug-resistant TB, and to patient support
Although the Stop TB Strategy entails standardized supervised
treatment and uninterrupted pharmaceutical supplies,47,48 several
prisons still encounter challenges in implementing supervised
treatment,38 the uncontrolled circulation and use of suboptimal
quality TB drugs,23,38,46,49 and TB/HIV treatment interactions in
prisons with a high co-infection prevalence.37 Some prisons
report that the provision of an effective pharmaceutical supply
may be in place, but that prisoners cannot afford treatment as they
pay out-of-pocket for health services.38,49 In addition, there are
often other factors affecting treatment adherence in prisons.
These may stem from a speciﬁc criminal culture among prisoners,
the concern of being cured and then referred back to prisons with
greater restriction, as well as the hierarchy among prisoners.
Approximately 30% of the studies included in a recent systematic
review described unsupervised treatment.31 Therefore, TB control
efforts should focus on the provision of effective treatment and/or
increasing effectiveness of treatment to TB patients,22,23,38,50
treatment adherence, and clinical case management.19,35
The high turnover of the prison population, between prisons
and to the wider community, is a major challenge. This facilitates
transmission and consequently the spread of both drug-sensitive
and drug-resistant forms of TB.19,23,51,52 Data from a systematic
review identiﬁed that 31.2% of studies struggled with effective
TB control due to loss to follow-up and a high turnover of
prisoners.31 Consequently, difﬁculties may be encountered in
diagnosing and treating TB, leading to the further spread of
infection to other prisoners, prison staff, and visitors.23 In addition,
approximately 26% of studies in the systematic review reported
that TB control in prisons was hampered by a ban on the prisoners
attending local clinics or hospitals for ‘security reasons’.31 Within
most prison systems, the follow-up of released prisoners is
limited or does not occur at all. In Eastern European countries,
approximately 60–70% of prisoners are not referred to TB facilities
after their release.53
3.1.3. Collaborative TB/HIV activities and the management of
comorbidities
A core challenge to TB control in prison systems is dealing with
the dual epidemics of HIV and TB, as well as other co-infections
such as with hepatitis B or C virus. Given the impact that HIV has on
TB cases and vice versa, coordination between TB and HIV
programmes is vital.54 However, this may be limited due to poorsurveillance of HIV among prisoners with TB,37 challenges in the
diagnosis of TB among people living with HIV,54,55 a lack of joint
planning and mobilization for TB/HIV co-infection, and inadequate
human resources capacity for managing TB/HIV.56,57 In many
prisons, the burden of HIV and hepatitis infections among TB
patients may be unknown, as periodic surveys or sentinel
surveillance are not performed and diagnostic testing and
counselling of TB patients is not implemented in all settings.56,58
Not all TB and HIV/AIDS programmes systematically coordinate
plans for the management of dual infections. There is a lack of
proper TB/HIV counselling and practice training for counsellors,
and of public education and awareness programmes for voluntary
HIV testing for individuals, resulting in TB patients not attending
HIV clinics. A lack of awareness and education also increases
stigmatization among prisoners, and the fear of HIV test results
leads to HIV testing being refused.57 Similar issues are seen for
hepatitis and other co-morbidities frequently detected among
prisoners. The epidemiological and clinical intertwining of other
determinants such as excessive alcohol use or injecting drug abuse
and chronic liver disorders (associated with hepatitis B or C virus)
with TB places a high burden on the health of prisoners, and also
after prisoners are discharged into the community.
Collaborative TB/HIV/hepatitis activities by NTPs and national
HIV/AIDS programmes should prioritize prisons, where the
prevalence of these infections is high. In addition, a coordinated
system, supported by the ministries of health, welfare, and justice
or interior, should implement a holistic approach to patients in
correctional facilities. Furthermore, preventive activities, including
wider health education (e.g. needle exchange or cleansing
programmes, or safe sex), should be promoted in order to
minimize the harms associated with high-risk behaviours.
3.1.4. Preventive treatment of persons at high risk
Despite the established evidence of the efﬁcacy of isoniazid
preventive therapy (IPT) in preventing TB among both HIV-
infected and HIV-uninfected individuals, this intervention has not
been fully explored in prisons. A systematic review of published
reports showed that only 18 studies were designed to address the
intervention in such settings.59 IPT may effectively interrupt the
progression of infection to active TB disease, but questions remain
regarding whether IPT should be started in a facility with short
imprisonment stays or in settings with high isoniazid resistance,
and also which institution should take responsibility for the
completion of IPT in the community once the prisoner is
released.19,60
3.2. Pillar 2: Bold policies and supportive systems
3.2.1. Political commitment with adequate resources for TB care and
prevention
Prison health services often have small budgets,45,60,61which, in
addition to the lack of skilled and motivated manpower,19,22,38
may jeopardize successful TB control programmes in prisons.
Public health attention from donors and other stakeholders
towards populations at risk of TB has increased in recent years
following the emergence of HIV/AIDS, the more stringent
application of human rights principles, health inequalities, and
health governance.62 Nevertheless, there are still challenges in TB
control in prisons due to logistical complications, a lack of political
commitment, and public indifference towards the prison popula-
tion,45 which undermine TB control programme efforts in prison
systems.
Improved and strengthened political commitment, including
sustainable funding,38,39,52 is therefore strongly recommended.31
The signiﬁcance of ensuring adequate funding for TB control in
prison systems is particularly important in Eastern Europe,
Table 2
Summary of infection control measures to be conducted in prisons
 Preventing the spread of infection from the community to prison by
intensiﬁed TB screening of new or transferred prisoners and preparing
special blocks ‘Quarantine’ or cells (to be used for 1–2 weeks) for new or
transferred prisoners
 Preventing TB infection among prisoners (transmission from one TB
prisoner to other prisoners) or to prison staff by conducting a contact
investigation for TB suspects and cases, improving infection control
(e.g., implementing organizational, administrative, and environmental
interventions) in prisons, and using IC for prisoners
 Preventing infection of family members and the community by a released
prisoner or prison staff by examining prisoners before release and
examining prison staff regularly
 Isolation measures for TB cases and/or suspects when patients are
screened or diagnosed within the prison system
TB, tuberculosis; IC, infection control.
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treatment. Besides the external funding provided by donors
(e.g., Global Fund, US Agency for International Development,
International Federation of Red Cross and Red Crescent Societies,
the World Bank, and bilateral donors), countries themselves
should allocate more local resources in order to gain sustained TB
control in prisons.63 As part of building political commitment, it is
essential to ensure that both legislation and national guidelines
facilitate TB control in prisons. In particular, the following areas
should have a supportive legal basis with minimum standards: (1)
guidelines in line with NTPs, (2) a sufﬁcient area per inmate to
avoid overcrowding, (3) adequate nutrition, (4) comprehensive IC
planning, (5) policies on the release of prisoners with TB and/or
their transfer to other facilities, and (6) and integration/collabora-
tion with health care services in the civil sector.64
Stewardship of prison health is deﬁned as ‘‘all issues concerning
governance and responsibility affecting the provision of prison
health services of an agreed standard’’.65 The question arising here
is which ministry should ideally be responsible for the stewardship
of health in prisons. This differs by country, and the general health
of prisoners may come under the responsibility of the ministry of
justice,66 the ministry of health, or the ministry of internal
affairs.65 The WHO Regional Ofﬁce for Europe Health in Prison
Project (HIPP) provides overall guidance to improve prison health
services.65 Presently, the ministries of health are in charge of
health in prisons in most settings.65 In other settings, there is a
need for close cooperation and collaboration between the
ministries of health and the ministries responsible for prisons to
plan common activities to improve TB control.
3.2.2. Engagement of communities, civil society organizations, and
public and private care providers
Prisoners belong disproportionately to population groups
already at high risk of TB (e.g., people who abuse substances,
the homeless, migrants from high endemic areas, and other
marginalized groups stricken by poverty with little or no access to
healthcare), which may partially explain the high prevalence of TB
in these settings.25,28,67 Education and counselling are fundamen-
tal to improving patient adherence to treatment. In some settings,
community representatives engage inmates in health education
and prepare them for treatment follow-up after their release from
prison. However, it is clear that prison health services alone may
not be able to fully respond to the TB situation in most settings;
therefore working in partnership on different levels needs to be
encouraged. Prison health services should collaborate closely with
other sectors, including civil society and community representa-
tives and health services outside prisons, in order to share
diagnostic facilities and improve the referral and support of
patients. Prison systems should also partner various ministries on a
political level, NGOs, donors, and health experts for improved
public awareness and knowledge-sharing.
3.2.3. Infection control
Many prisons worldwide are overcrowded, well beyond their
ofﬁcial capacity.68 Overcrowded prisons facilitate the spread of
mycobacterial strains, as prisoners are in close contact with one
another, often for 12 h or more each day without access to fresh air.
In some countries, the living conditions of prisoners are poor:
spaces in prison cells of less than one square meter per person,
bunks stacked three tiers high, and prisoners sleeping in turn,
even during daytime hours when they have access to an outside
area, or they are kept in isolation cells for long periods without
spending time outside at all.53,68
Overcrowding, poor ventilation, and prolonged conﬁnement
inside cells are all factors conducive to the transmission of airborne
infections. Poor ventilation may be due to inadequate prisoninfrastructure (e.g., lack of windows, no mechanical ventilation), or
caused by the prisoners themselves covering the windows to block
cold air from entering the room in cold climates, or by hanging
clothes on the bars. The lack of mechanical ventilation systems is
another major risk factor for contracting TB.45 Furthermore, many
prisoners may be heavy smokers, adding to the unhealthy
environment of overcrowded cells.68
Overcrowding leading to signiﬁcantly higher rates of TB
transmission in prisons also has implications for rates of TB in
the community. Using longitudinal TB and cross-sectional MDR-TB
data from 26 Eastern European and Central Asian countries,
Stuckler et al.28 found that each percentage increase in incarcera-
tion rate related to an increased TB incidence of 0.34% (population
attributable risk, 95% conﬁdence interval 0.10–0.58%, p < 0.01),
after controlling for several confounders. Conversely, a reduction
in custodial sentencing would impact favourably on risk reduction
of TB and MDR-TB in the general population.69
In light of the challenge of overcrowding associated with
increased rates of TB in both the prison and community setting, TB
IC is a fundamental element for improved TB control.70 TB IC is a
combination of measures aimed at minimizing the risk of MTB
transmission and includes the early and rapid identiﬁcation of
individuals with suspected or known TB, separation of prisoners
according to their TB disease type, and effective treatment of
infection or disease,69,71 building design or engineering methods
to improve ventilation, disinfecting of the air, and the use of
protective measures for staff and visitors in contact with TB
patients. TB IC is also a fundamental element of Pillar 2 of the post-
2015 End TB Strategy.30 A list of IC measures to be conducted in
prisons in consideration of these factors is summarized in
Table 2.72
3.3. Pillar 3: Intensiﬁed research and innovation
One of the three main pillars of the End TB Strategy includes
research. With the current 2% decline in TB incidence, the MDGs
for TB control will not be met by 2015.73 The need to develop
new technologies to accelerate TB control resulted in the launch
of the TB Research Movement, with the development of a
roadmap for global TB research as its main objective.73,74 Despite
its impact on public health, TB control in prisons has been given
a low priority by national health authorities worldwide,
particularly in LMICs. This is reﬂected negatively in the fund
allocation, and consequently in research output.75–77 A recent
review of published documents describing TB research priorities
showed that 33 documents were published from 1998 to
2010 describing the importance of research on new medicines
and diagnostics.78 None of the documents retrieved directly
addressed TB research in prisons.
Table 3
Priorities for research related to TB control in prisons
Epidemiological research
Actual burden of TB (drug-susceptible and drug-resistant strains) and TB/HIV
in prisons worldwide
Best tools to measure the TB burden
Social determinants of TB infection and transmission inside prisons
Prevalence of LTBI in high-burden countries
Impact of scaling up current preventive regimens on TB prevalence in prisons
Contribution of TB in prison to TB transmission in the community
(attributable risk)
Operational (health services) research
Best operational model to enhance case-ﬁnding and its impact on mortality
and transmission in prisons
Deﬁnition of optimal algorithms for the diagnosis of all forms of active TB
and the best model to rule out TB among high-risk groups (particularly the
HIV-infected)
Barriers to achieving treatment adherence and strategies to improve treatment
management particularly after prisoner release after a short detention
Impact of individual infection control methods and proper cost-effective
methods for its implementation
Cost-effectiveness studies of the scaling-up of TB/HIV and MDR-TB services in
prisons
Best model to integrate TB/HIV/STD services
Proper reporting and recoding system suitable for prisons
Diagnostics
New point of care, same-day diagnostic tool to diagnose active TB
Rapid tests for diagnosing drug-resistant TB
Feasibility, impact, and cost-effectiveness of new automated nucleic acid
ampliﬁcation tests (e.g. GeneXpert) for use in prisons in remote and/or
resource-limited settings, particularly for new arrival screening
Optimal and cost-effective modelling for diagnosing LTBI and active TB
Developing a proper diagnostic tool to differentiate between LTBI and active
TB, particularly among HIV-infected prisoners
Treatment
Newer and safer TB medications to combat the growing epidemic of TB and
M/XDR-TB in prisons
Shorter treatment regimens to treat LTBI and active TB
Effectiveness and safety of currently available LTBI treatment regimens in
correctional settings vis-a`-vis the high prevalence of blood-borne
co-infections (i.e., HIV, HCV, HBV)
Safety, efﬁcacy, and cost-effectiveness of new shorter LTBI regimens (e.g.,
combination of isoniazid and rifapentine once weekly for 12 weeks)
Optimal time to start ARV and exploration of possible drug–drug interactions
with newer TB medications
TB, tuberculosis; LTBI, latent tuberculosis infection; MDR, multidrug-resistant; STD,
sexually transmitted disease; M/XDR-TB, multi- and extensively drug-resistant TB;
HCV, hepatitis C virus; HBV, hepatitis B virus; ARV, antiretroviral.
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important to adequately estimate the burden of disease and the
risk of developing TB in prison.79 Given the difference in dynamics
and population, guidelines outlining TB research priorities need
to be developed speciﬁcally for correctional institutions.76 The
areas for research to be addressed in relation to prisons, as listed
in Table 3, are of high priority.74,75,78 There are still concerns
about conducting studies among vulnerable populations, including
prisoners, and ethical considerations related to prisoners need
to be addressed properly when conducting research in these
settings.
4. Conclusions
Currently, a complex range of activities is required to tackle the
alarming situation of TB, M/XDR-TB, and TB/HIV control in prisons.
The requirements for enhanced TB control in prisons are good
governance, clear strategies to diagnose and treat TB patients,
adherence to internationally established IC policies, and the
performance of cost-effectiveness analyses to evaluate screening
procedures and other control strategies. Released prisoners with
active TB disease need to be followed-up by health authorities inthe civilian sector and NTP-based local health centres, or
organizations collaborating with NTPs. To minimize the interrup-
tion of treatment for released prisoners, implementation of the
following interventions is recommended: (1) discharge or referral
planning, (2) post-release follow-up, and (3) notiﬁcation of
unplanned releases and monitoring of referrals. If NTPs or
ministries of health are responsible for TB control in the prison
system, the establishment of follow-up mechanisms is probably
more likely to occur, and gaps between public health and prisons
are less likely to exist.
In addition, it is crucial to prepare effective plans for human
resource development covering entire processes, such as basic
education (in- and pre-service), retraining, on-the-job training,
supervision, career development, salary scales, job descriptions,
and enhanced IC measures. Although the directly observed therapy
strategy (DOTS) has been declared the most cost-effective health
strategy available by the World Bank, there is still work to be done
to improve general TB management among prisoners. It is argued
that if there is a failure to implement TB control successfully in
prisons, it will affect prison and public health services dramatically
in the near future, due to increased numbers of cases within the
prison services and community, as well as higher numbers of M/
XDR-TB and/or TB/HIV cases. New tools, such as the GeneXpert
MTB/RIF, should be implemented in central prison hospitals, or
facilities where prisoners receive TB treatment.
Although we are entering an exciting period of innovation, e.g.
introduction of GeneXpert MTB/RIF and new medicines like
delamanid and bedaquiline,41,80,81 TB control in prisons remains
a neglected priority. In addition, the increased cost of new drugs
(USD 900 and USD 3000 for bedaquiline in LMICs and high-income
countries, respectively, for a 6-month course)82 and the resources
needed for pharmacovigilance and the management of side
effects, remain a barrier to utilization, particularly in the prison
sector where resources are even more limited. No real improve-
ment can be facilitated without clear commitment from national
governments and partnerships and sustained ﬁnancing, in line
with the End TB Strategy. In order to achieve this, the principle
‘‘good prison health is good public health’’83 needs to be fully
recognized.
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